Focus Partners Wealth Decreases Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Focus Partners Wealth reduced its holdings in Regeneron Pharmaceuticals by 35.3%, selling 3,238 shares and retaining a total of 5,946 shares worth approximately $3.77 million.
• Regeneron Pharmaceuticals reported a quarterly earnings per share of $12.89, significantly exceeding analysts' expectations, with revenue of $3.68 billion, reflecting a 3.6% increase year-over-year.
• The stock currently has a consensus rating of "Moderate Buy" from analysts, with a target price averaging around $817.67.

Focus Partners Wealth reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 35.3% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 5,946 shares of the biopharmaceutical company's stock after selling 3,238 shares during the period. Focus Partners Wealth's holdings in Regeneron Pharmaceuticals were worth $3,772,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC increased its position in shares of Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after acquiring an additional 686 shares during the last quarter. American Assets Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth $427,000. Snowden Capital Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 7.2% in the 4th quarter. Snowden Capital Advisors LLC now owns 1,617 shares of the biopharmaceutical company's stock valued at $1,152,000 after buying an additional 108 shares during the last quarter. Teza Capital Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 49.6% in the fourth quarter. Teza Capital Management LLC now owns 1,294 shares of the biopharmaceutical company's stock valued at $922,000 after buying an additional 429 shares during the period. Finally, Tidal Investments LLC raised its position in shares of Regeneron Pharmaceuticals by 21.5% in the 4th quarter. Tidal Investments LLC now owns 7,715 shares of the biopharmaceutical company's stock worth $5,496,000 after acquiring an additional 1,365 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on REGN shares. Canaccord Genuity Group restated a "buy" rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Rothschild & Co Redburn began coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a "buy" rating and a $890.00 target price on the stock. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a report on Thursday, August 14th. Guggenheim increased their target price on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Finally, UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Stock Down 0.5%

Shares of NASDAQ REGN traded down $2.96 during trading hours on Friday, hitting $595.75. 644,264 shares of the stock were exchanged, compared to its average volume of 1,091,444. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The company has a market cap of $63.14 billion, a PE ratio of 15.03, a PEG ratio of 1.96 and a beta of 0.35. The firm has a fifty day moving average price of $567.29 and a 200-day moving average price of $576.47. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,154.56.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the prior year, the business posted $11.56 EPS. Regeneron Pharmaceuticals's revenue for the quarter was up 3.6% compared to the same quarter last year. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.